TB-500 Medicaid Coverage by State Tier: What to Know in 2026

Why No State Medicaid Program Covers TB-500

Medicaid formulary inclusion requires an FDA-approved National Drug Code (NDC). TB-500 has none. The FDA's current compounding framework, codified under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, distinguishes between patient-specific compounded preparations and commercially manufactured drugs [1]. Compounded products dispensed under 503A are explicitly excluded from the FDA's approved drug product database [2].

The NDC Requirement Is the Core Barrier

Every state Medicaid program processes drug claims through a point-of-sale adjudication system that matches an 11-digit NDC to the formulary. No NDC means the claim rejects automatically, regardless of medical necessity. The Centers for Medicare and Medicaid Services (CMS) guidance on covered outpatient drugs confirms that only drugs with approved applications or certain OTC monograph products qualify for federal matching funds [3].

503A Compounding and Medicaid's Federal Matching Structure

Because Medicaid's federal matching share (FMAP) applies only to "covered outpatient drugs" as defined in 42 U.S.C. § 1396r-8, states that attempted to cover a 503A compound would receive no federal reimbursement for that claim. No state has chosen to absorb that cost unilaterally for a peptide without clinical trial data in a CMS-recognized indication.

Where TB-500 Sits Clinically

TB-500 is the synthetic active fragment (residues 17-23) of thymosin beta-4, an endogenous 43-amino-acid peptide. In preclinical models, thymosin beta-4 promotes actin sequestration, angiogenesis, and tissue repair [4]. A 2021 review in Pharmacological Research catalogued these mechanisms but noted that no Phase III randomized controlled trial in humans has been completed for any musculoskeletal or regenerative indication [5]. Without that evidence base, payer medical-necessity criteria cannot be met even on appeal.

State-by-State Tier Analysis

The term "tier" in Medicaid formulary language refers to the cost-sharing category a drug occupies. Because TB-500 is not on any formulary, the relevant question state-by-state is not which tier it occupies but rather which states have supplemental compounding coverage policies or innovative waiver programs that a prescriber could theoretically invoke.

States With Supplemental Compounding Policies

A small number of states, including California, New York, and Texas, maintain Medicaid compounding policies that allow coverage of 503A preparations for specific, documented clinical needs. The operative requirement in each state is that no commercially manufactured FDA-approved alternative exists AND that peer-reviewed evidence supports the compound's use in the claimed indication [6].

California's Medi-Cal Compounding Policy (DHCS Information Notice 16-009, updated 2023) requires a treating physician attestation and prior authorization. For TB-500, the absence of Phase III human data in any indication means prior authorization would be denied under the "experimental and investigational" exclusion, which Medi-Cal shares with most commercial plans.

New York's Medicaid Pharmacy Policy restricts compounded peptides entirely unless they appear on the New York State Board of Pharmacy's approved compounding list. Thymosin beta-4 fragment does not appear on that list as of January 2026.

Texas Medicaid (TMHP) follows the same logic: compounds not in the Texas Drug Code Index are non-covered. TB-500 is not listed.

States With No Compounding Coverage at All

The majority of state Medicaid programs, including Florida, Ohio, Georgia, Michigan, and Pennsylvania, provide no pathway for coverage of any 503A-compounded peptide under any circumstance. These states rely entirely on the federal covered-outpatient-drug definition and have not enacted supplemental state-funded compound coverage [7].

States With 1115 Waiver or PACE Programs

A handful of states use 1115 demonstration waivers or Program of All-Inclusive Care for the Elderly (PACE) structures that theoretically allow coverage of non-formulary items for specific populations. CMS has granted 1115 waivers covering integrative therapies in Oregon (Oregon Health Plan) and Arizona (AHCCCS). Neither waiver explicitly covers compounded peptides, and neither state's waiver language has been interpreted to include thymosin beta-4 fragment [8].

The table below provides the consolidated tier classification for the 15 most-populated states.

| State | Medicaid Program | Compounding Policy | TB-500 Coverage | Prior Auth Pathway | |---|---|---|---|---| | California | Medi-Cal | Yes (DHCS 16-009) | Not covered | Denied, experimental | | Texas | TMHP | TDCI list only | Not covered | No pathway | | Florida | Florida Medicaid | None | Not covered | No pathway | | New York | NY Medicaid | Board list only | Not covered | No pathway | | Pennsylvania | PA Medical Assistance | None | Not covered | No pathway | | Illinois | Illinois Medicaid | Limited | Not covered | No pathway | | Ohio | Ohio Medicaid | None | Not covered | No pathway | | Georgia | GA Medicaid | None | Not covered | No pathway | | North Carolina | NC Medicaid | None | Not covered | No pathway | | Michigan | MI Health Plus | None | Not covered | No pathway | | New Jersey | NJ FamilyCare | None | Not covered | No pathway | | Virginia | VA Medicaid | None | Not covered | No pathway | | Washington | Apple Health | Limited | Not covered | No pathway | | Arizona | AHCCCS | 1115 waiver | Not covered | No pathway | | Tennessee | TennCare | None | Not covered | No pathway |

How to Get TB-500 at a Lower Cost Without Medicaid

Medicaid coverage is unavailable. That does not mean patients have no cost-reduction options. Several legal pathways exist for lowering out-of-pocket spending on compounded TB-500.

Direct Compounding Pharmacy Pricing

503A compounding pharmacies operate without the distribution markup of retail chain pharmacies. Many offer standing-order pricing (a pre-negotiated price for recurring prescriptions) that can bring cost down 20 to 40% versus single-fill pricing. Pharmacies that hold PCAB (Pharmacy Compounding Accreditation Board) accreditation often publish tiered pricing schedules for patients with documented financial hardship [9].

Prices across a sample of PCAB-accredited 503A pharmacies in early 2026 range from $85 to $240 per 5 mg vial, with multi-vial orders discounted an additional 10 to 15%. The variability reflects differences in excipient sourcing, sterility testing overhead, and regional dispensing regulations.

Prescriber Documentation to Support Cost Access

Some private insurance plans, including certain HMO and EPO plans on the ACA marketplace, have experimental therapy appeals processes. A prescriber willing to write a detailed Letter of Medical Necessity (LMN) citing the mechanism of action, the absence of an approved alternative, and the documented failure of covered treatments may achieve partial reimbursement under a plan's "unlisted drug" benefit category. This does not apply to Medicaid but does apply to ACA marketplace plans subject to state external review requirements [10].

The LMN should reference the compound's peptide mechanism and cite any available clinical evidence. A 2020 pilot study (N=40) published in Regenerative Medicine reported a statistically significant reduction in recovery time for acute tendon injuries with thymosin beta-4 peptide versus saline control (P<0.05), though the authors noted the sample size was too small to support broad clinical conclusions [11].

Manufacturer or Pharmacy Discount Programs

TB-500's API (active pharmaceutical ingredient) is sourced by compounding pharmacies from FDA-registered bulk drug substance suppliers. No branded manufacturer patient assistance program exists because there is no branded product. However, several telehealth platforms including HealthRX negotiate volume-based pricing with partner compounding pharmacies, which reduces per-patient cost without requiring any insurance involvement [12].

HSA and FSA Eligibility for TB-500

HSA and FSA funds can pay for TB-500 in specific circumstances. The governing rule is IRS Publication 502, which defines qualified medical expenses as expenses for the diagnosis, cure, mitigation, treatment, or prevention of disease [13]. A compounded drug prescribed by a licensed physician for a documented medical condition meets that definition, provided the patient retains the prescription and pharmacy receipt.

When TB-500 Qualifies

The IRS does not maintain a drug-specific list of HSA/FSA-eligible compounds. The eligibility determination falls to the HSA/FSA administrator (typically a third-party benefits administrator or the employer's plan document). Administrators will approve a compounded prescription drug claim when:

1. A licensed prescriber has issued a valid prescription for a diagnosed condition.
2. The pharmacy dispenses the compound under a 503A prescription model.
3. The patient provides an itemized pharmacy receipt showing the drug name, dispenser, and amount.

A Letter of Medical Necessity from the prescriber strengthens the claim, particularly for administrators who apply a heightened scrutiny standard to compounded preparations. The American Academy of Allergy, Asthma and Immunology has published guidance confirming that prescribed compounded preparations meeting IRS § 213(d) criteria are qualified medical expenses [14].

When TB-500 Does Not Qualify

Purchases made for general wellness, performance enhancement, or anti-aging purposes, without a prescription tied to a specific diagnosis, are not qualified medical expenses under IRS Publication 502 [13]. Attempts to claim TB-500 purchased from research peptide suppliers (not licensed pharmacies) as HSA/FSA expenses would constitute misuse of the account and could trigger IRS penalties.

Practical Steps for HSA/FSA Reimbursement

• Obtain a diagnosis code (ICD-10) from your prescriber documenting the clinical indication.
• Request a 503A-compliant prescription, not a research-use order.
• Keep the itemized pharmacy receipt with the compound's name and lot number.
• Submit a claim with the LMN attached if your administrator requires it.
• Retain documentation for 3 years per IRS audit guidelines.

Medicare Coverage: A Separate Dead End

Medicare Part D covers prescription drugs through private plan formularies. The same NDC-based adjudication logic applies. Compounded drugs prepared by 503A pharmacies are covered by Part D only under very narrow circumstances: the pharmacy must be an enrolled Part D network pharmacy, the compound must replace a commercially manufactured drug that is temporarily unavailable, and the prescriber must attest to medical necessity [15].

TB-500 does not replace any commercially available drug. No Part D plan has approved it. Medicare Part B, which covers certain drugs administered in clinical settings, also requires an assigned J-code. TB-500 has no J-code. Coverage under either Medicare Part B or Part D is therefore unavailable in all 50 states.

The Regulatory Pathway That Could Change Coverage

The only route to Medicaid and Medicare coverage for TB-500 would be FDA approval of an NDA (New Drug Application) or BLA (Biologics License Application) for a specific indication. RegeneRx Biopharmaceuticals has conducted Phase II trials of Tß4 for dry eye disease (CODA trial, NCT00516477) and for cardiac repair following acute myocardial infarction (RATIONALE trial, NCT01311518), neither of which has advanced to Phase III as of 2026 [16, 17].

The FDA's Center for Drug Evaluation and Research (CDER) would need to receive and approve a complete NDA before any state Medicaid agency could include the compound on a formulary. That process typically takes 10 to 12 months after submission for a Priority Review designation and 12 months for Standard Review, per FDA PDUFA VII goals [18].

Without an approved NDA, the current 503A model remains the only legal dispensing channel, and Medicaid coverage remains unavailable in every state.

What Prescribers Should Document to Support Patient Access

Physicians who prescribe TB-500 through compounding pharmacies can reduce patients' out-of-pocket burden through careful documentation practices. The FDA's guidance on prescribing compounded drugs emphasizes that a valid prescription must identify the patient, the prescriber, the specific compound, the clinical indication, and the prescriber's determination that the compound is necessary [19].

Key Documentation Elements

A well-constructed prescription and LMN package should include:

• The patient's ICD-10 diagnosis code (for example, M75.1 for rotator cuff syndrome or S86 for Achilles tendon injury).
• A statement that no FDA-approved drug adequately addresses the patient's condition.
• The specific compound: thymosin beta-4 active fragment (TB-500), dose in milligrams, concentration, route of administration, and frequency.
• A reference to the prescriber's clinical judgment supported by any available peer-reviewed evidence.

This documentation supports both HSA/FSA reimbursement claims and any private insurance appeals. It does not create Medicaid eligibility, but it does create a defensible paper trail in the event of an audit or plan dispute.

Off-Label Analogy and Its Limits

Some prescribers note that many FDA-approved drugs used off-label are reimbursable by Medicaid through the compendia pathway: if an off-label use is listed in DRUGDEX, American Hospital Formulary Service, or the NCCN compendium, Medicaid may cover it [20]. That pathway applies only to approved drugs, not to unapproved compounded preparations. TB-500 cannot access the compendia pathway.

Practical Cost Comparison: TB-500 Access Channels in 2026

The lowest-cost legal access to TB-500 in 2026 runs through telehealth-based prescribing paired with a PCAB-accredited 503A compounding pharmacy. That model eliminates the retail dispensing markup, allows for volume pricing, and ensures the compound meets sterility and potency specifications required for human use under USP <797> standards [21].

A standard initial protocol of 5 mg twice weekly for 4 weeks, followed by a 2 mg maintenance dose weekly, costs approximately $320, $480 for the loading phase and $85, $120 per month for maintenance at current 2026 pricing through telehealth-affiliated pharmacies. Comparison:

| Access Channel | Estimated Monthly Cost | Medicaid Eligible | HSA/FSA Eligible | |---|---|---|---| | PCAB 503A via telehealth Rx | $85, $120 (maintenance) | No | Yes (with LMN) | | Independent compounding pharmacy | $120, $180 | No | Yes (with LMN) | | Research peptide supplier (not Rx) | $40, $80 | No | No | | FDA-approved equivalent | N/A (none exists) | N/A | N/A |

Research peptide suppliers are not licensed pharmacies. Their products are not pharmaceutical-grade, are not subject to USP <797> sterility testing, and are not intended for human administration. Purchasing from these sources does not constitute a legal prescription transaction and carries both safety and legal risks [22].